- Home
- APLS
as 06-20-2025 4:00pm EST
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.2B | IPO Year: | 2017 |
| Target Price: | $37.67 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.10 - $42.47 | Next Earning Date: | 07-31-2025 |
| Revenue: | $775,839,000 | Revenue Growth: | 48.04% |
| Revenue Growth (this year): | 1.01% | Revenue Growth (next year): | 22.14% |
Latest Apellis Pharmaceuticals Inc. News
APLS Breaking Stock News: Dive into APLS Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?
Clinical Trials Arena
12 days ago
Sobi and Apellis report new data from Phase III trial for C3G and IC-MPGN
TipRanks
14 days ago
Apellis, Sobi present data from open-label period of Phase 3 VALIANT study
Zacks
15 days ago
Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?
MT Newswires
15 days ago
Apellis Pharmaceuticals, Sobi Report Empaveli's Sustained Efficacy at 1 Year in Phase 3 Study
GlobeNewswire
15 days ago
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
Simply Wall St.
16 days ago
High Growth Tech Stocks To Watch In The US June 2025
GlobeNewswire
17 days ago
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Compare APLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLS Apellis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.